Introduction
Adult T-cell leukemia (ATL) is a highly aggressive lymphoproliferative malignancy of helper T lymphocytes and is etiologically linked to human T-cell leukemia virus type I (HTLV-I).
1,2 After a latency period of decades, a small proportion of carriers (~5%) develops ATL. Among subtypes of ATL, smoldering and chronic ATL are considered to be low-grade malignancies because of their indolent clinical courses, although they frequently progress to acute or lymphoma-type ATL with aggressive clinical behaviors after several years. 3 It has been thought that the HTLV-I-mediated T-cell transformation arises from a multistep oncogenic process and that additional factors other than viral proteins are involved in leukemogenesis of ATL. 4 In fact, although host genetic changes such as mutation of TP53 [5] [6] [7] and Fas, 8, 9 or deletion of CDKN2A, 10,11 CDKN2B 10 and KIP1 12 were reported in ATL, they were predominantly observed in aggressive forms of ATL including acute and lymphoma types. In addition to the genetic alterations, gene silencing by DNA methylation has been reported in a few genes encoding proteins with functions in cell growth control and apoptosis, 13, 14 suggesting that epigenetic changes were also implicated in the leukemogenesis.
Thus, identification of genes that are preferentially methylated in ATL would be potentially useful for several reasons: first, it would help to study whether such events in genes may predispose the cells to neoplastic transformation. Second, such methylation profiles would be useful to distinguish ATL at advanced stages from the disease at early stages. Finally, change of the methylation patterns in a single patient may help in predicting progression of the disease.
Transforming growth factor- (TGF-) is a multi-functional cytokine that controls cellular responses including the induction of cell growth inhibition, differentiation, and apoptosis. [15] [16] [17] [18] [19] These cellular responses are thought to define the role of TGF- as a tumor suppressor. Although perturbation of TGF- signaling has been implicated in oncogenesis 4 of human solid tumors, [15] [16] [17] [18] [19] the role of aberrant TGF- signaling in leukemogenesis has not been well delineated. TGF- signals through ligation of the TGF- receptor type II (TR), which results in activation of TGF- receptor type I (TR) and leads to assembly of the heterodimeric receptor complex. 20 The TR propagates the signal by phosphorylating the intracellular mediators Smad2 and Smad3 that subsequently hetero-oligomerize with a common partner Smad4 to enter the nucleus where transcription of TGF- target genes is regulated. 20 Bone morphogenetic proteins (BMP), belonging to the members of the TGF- superfamily, were originally identified as molecules that induce bone and cartilage formations, and are now considered multifunctional cytokines. 21, 22 To date, over 20 BMPs have been characterized, and can be subdivided into several different classes. 23 In various human malignacies, as with TGF-, BMPs are thought to be important regulators of cell differentiation and proliferation frequently in an inhibitory manner. For example, loss of BMP-2 expression was reported in cancers of the prostate, colon and stomach. [24] [25] [26] Inactivation of BMP-3 and BMP-6 was suggested to promote development of lung cancer. [27] [28] [29] Moreover, the important role of BMP-3 silencing in the development of colorectal tumor has been shown. 30 However, the underlying mechanism of the loss of BMPs expression in malignant diseases has not been well defined.
Of these BMPs, the BMP-6 gene came into the focus of our interest in DNA methylation study because the BMP-6 promoter sequence was previously identified as a target for aberrant DNA methylation. 31 Recently, promoter methylation of the BMP-6 gene and the resultant gene suppression have been shown often in aggressive types of malignant lymphomas. 32 These findings prompted us to examine whether such methylation is also present in leukemia.
The present study was designated to determine the methylation status of the BMP-6 gene in various types of leukemias. We found that frequent methylation and the resultant loss of 5 BMP-6 expression in ATL, especially in acute and lymphoma types. On the other hand, little methylation was observed in other types of leukemias including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The 387-bp amplicon contains six BstUI restriction sites ( Fig. 1) . On full or partial digestion, digested fragments with various sizes are generated depending on sites of methylation of the CpG pairs. The resultant DNA fragments were electrophoresed on 2.5% agarose gels and visualized by ethidium bromide staining.
Materials and methods

Patients
The digested fragments correspond to methyalted DNA. 33 
Bisulfite genomic sequencing
The PCR products were purified with the Gel Extraction kit (Bionex, Seoul, Korea), cloned into pGEM-T Easy vector (Promega, Madison, WI), and transformed into Escherichia coli. Plasmid DNA from the isolated clones containing the insert was purified using the FlexiPrep kit (GE Healthcare Bio-Sciences, Piscataway, NJ). Six clones for each leukemia sample were sequenced with the pUC/M13 primer. The DNA sequence was determined by using the BigDye Terminator Cycle Sequencing kit ver.1.1 (Applied Biosystems, Foster City, CA) and an ABI 3130 automated DNA sequencer. 
Reverse-transcription-PCR
Total RNA was isolated using the Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Before RT, a total of 1 g of RNA was treated with DNase I (Invitrogen) to remove any DNA contaminant. The DNase I-treated RNAs were subjected to reverse-transcription (RT) with ThermoScript reverse transcriptase (Invitrogen), as previously described. 34 The cDNAs samples (equivalent to the cDNA amount from 50 ng of initial total RNA) were PCR-amplified, and the products were electrophoresed on 2.0 % agarose gels 
Western blot analysis
Proteins (corresponding to 2 x 10 4 cells) were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and electrophoretically transferred onto a polyvinylidene difluoride membrane, as previously described. 34 The filter was incubated with the mouse anti-BMP-6 monoclonal antibody, and the second-step reaction was performed by incubation of the washed filter with a horseradish peroxidase-conjugated rabbit anti-mouse antibody. Reactive proteins were detected by incubation of the washed filter in the enhanced chemiluminescence system according to the manufacturer's instructions (GE Healthcare Bio-Sciences) followed by exposure to an autoradiographic film. The -actin mAb was used in parallel to confirm 
5-aza-2'-deoxycytidine treatment
Two ATL cell lines, MT-1 36 and ATL-1K 37 , were incubated in RPMI 1640 medium supplemented with 10% fetal calf serum in the presence or absence of 3 M of the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC; Sigma, St. Louis, MO) for 6 days.
The cells were split on day 3 with the addition of fresh drug. After the drug treatment, cells
were harvested for DNA and RNA extractions.
Results
Methylation analysis of the BMP-6 gene in leukemias
We screened mononuclear cells of peripheral bloods or bone marrow aspirates from pretreated patients with various types of leukemias for the presence of promoter methylation of the BMP-6 gene using the COBRA method. COBRA analysis is a well-characterized method for DNA methylation studies, and has been done largely before.
33 Table I summarizes the result of methylation study for each group of leukemia. The promoter methylation of the BMP-6 gene was found in 3 of 67 (5%) AML samples, 6 of 38 (16%) ALL samples, and 1 of 21 (5%) CLL samples. Among methylation-positive ALL samples, 3 of 6 (50%) had T-cell phenotype, and the methylation was found in 3 of 5 (60%) of T-cell ALL.
Of note, higher frequency of the BMP-6 promoter methylation was found in ATL samples (49 of 60; 82%) compared with other leukemias studied (10 of 126; 8%) (P < 0.001). Among subtypes of ATL, there was a trend for more frequent methylation in aggressive ATL forms of acute type (27 of 28; 96%) and lymphoma type (17 of 18; 94%) than indolent forms of 9 chronic type (4 of 9; 44%) and smoldering type (1 of 5; 20%) (Table I ). Figure 2 shows representative results of COBRA in ATL. Furthermore, we evaluated the methylation status of PBMCs from seven healthy donors and 22 non-malignant lymph nodes with reactive lymphadenopathy, none of which showed detectable BMP-6 promoter methylation (Table I) .
In these methylation analyses, the two lymphoma cell lines, Akata and SP-53, were employed in parallel as BMP-6 methylation-positive and -negative controls, respectively. The BMP-6
promoter of Akata cells were previously proven to be fully methylated by the bisulfate sequencing analysis, while SP-53 cells showed no evidence of the methylation.
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Bisulfite sequencing analysis
To confirm the methylation at CpG sites of the BMP-6 promoter region, the ATL samples and a smoldering case (S-5) were subjected to bisulfite sequencing. The PCR products were cloned into a plasmid vector, and six independent clones were sequenced. As shown in Figure 3 , the bisufite sequencing showed good concordance with COBRA. In cases found to be highly methylated by COBRA (A-8, A-10, A-23, and L-10), extensive methylation across the CpG islands was seen, whereas the sample S-5 in which methylation was not be found by COBRA showed little methylation at CpG sites of the promoter region.
Association of the BMP-6 promoter methylation with transcriptional gene silencing
To elucidate whether the aberrrant methylation of BMP-6 is associated with loss of BMP-6 expression, we analyzed expression of BMP-6 transcripts by RT-PCR with cycles that amplified the -actin cDNA to plateau levels. Representative results are shown in Figure 4a .
ATL samples with little BMP-6 promoter methylation such as smoldering and chronic types expressed BMP-6 mRNA transcripts, whereas samples with BMP-6 promoter methylation (acute and lymphoma types) did not have detectable BMP-6 mRNAs. These results suggested that the BMP-6 promoter methylation correlated with loss of BMP-6 expression.
We next assessed the association between this epigenetic aberration and transcriptional inactivation of the BMP-6 gene at the protein levels (Fig. 4b) . 
Restoration of BMP-6 expression by the demethylation agent
To confirm that this loss of expression was due to the BMP-6 promoter methylation, two ATL cell lines MT-1 and ATL-1K were incubated in the presence or absence of the 5-aza-dC, and methylation status and BMP-6 mRNA expression were analyzed by COBRA and RT-PCR, respectively. In this COBRA study, the proportion of methylated (M) versus unmethylated (U) products (digested versus undigested) was semiquantitated by using a densitometer to compare percent methylation between two samples before and after 5-aza-dC treatment. The percent methylation was calculated as follows according to the previous report: M/(M + U) x 100.
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Both MT-1 and ATL-1K cells had extensive promoter methylation of the BMP-6 gene, but treatment with 5-aza-dC led to partial demethylation (Fig. 5a ). In parallel with the demethylation, there was re-expression of the BMP-6 transcripts (Fig. 5b) , implying that the methylation pattern is associated with transcriptional silencing.
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Clinical aspects of BMP-6 promoter methylation in ATL patients
Chronic ATL, characterized as an indolent clinical form, later progresses to aggressive forms. 3 Of the chronic ATL patients investigated in this study, none of four cases (C-4, -5, -6, and -7) completely negative for BMP-6 promoter methylation showed progression to acute ATL during the follow-up period (more than 3 years). On the other hand, four (C-2, -3, -8
and -9) of five cases with slight methylation progressed to acute or lymphoma-type ATL within a few years. This may suggest that BMP-6 promoter methylation-positive cases tended to progress to acute crisis more shortly than methylation-negative cases. Figure 6 shows different patterns of the BMP-6 promoter methylation and its gene expression in cases 
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Overexpression of BMP-6 in murine epidermis suppressed skin tumor formation. 41 Second, decreased expression of BMP receptor type II correlated with resistance to the growth-inhibitory effect of BMP-6 in renal cell carcinoma, suggesting that loss of sensitivity to BMP-6 is necessary to achieve the malignant phenotypes. 42 Finally, epigenetic inactivation of BMP-6 by gene promoter methylation was suggested to promote lung tumor development. 43 Furthermore, BMP-6 promoter methylation was observed in a subset of breast cancer cells. 44 In the realm of hematological malignancies, BMP-6 inhibited proliferation and induce apoptosis of myeloma cells. 45 Recently, we have reported that promoter methylation of the BMP-6 gene was found more often in aggressive types of malignant lymphomas. 32 In this study, we analyzed methylation status of the BMP-6 promoter in 186 leukemia samples. We found a significant higher frequency of the methylation in ATL (82%) than other types of leukemias including AML, ALL, and CLL (8%) (P < 0.001). The findings indicate that the BMP-6 gene appeared to be preferentially methylated in ATL. Of note, the BMP-6 gene was more frequently methylated in aggressive types of ATL (acute and lymphoma types; 96%) than less malignant types of ATL (chronic and smoldering types; 36%) (P < 0.001). Among T-cell ALL tested, 3 of 5 (60%) was positive for BMP-6 promoter methylation. We also showed methyaltion of the BMP-6 gene was correlated with decreased mRNA transcript and protein expression. Furthermore, the transcriptional repression was reversible by treatment with the demethylating agent 5-aza-dC. Thus, these findings suggested that methylation was responsible for the transcriptional silencing. Our data are, to the best of our knowledge, the first demonstration of epigenetic inactivation of the BMP family member in leukemia.
Although many ATL patients initially manifest growth of leukemic clones without 13 apparent clinical symptoms, most individuals in the chronic stages eventually undergo progression to aggressive stages. 3 Among chronic ATL cases, some patients progress to the aggressive stages shortly, other patients show no progression for a long time. Therefore, identification of the subgroup of chronic ATL patient who will progress to acute crisis shortly is clinically important. Although the number of cases studied was relatively small, our data suggested that chronic ATL cases with BMP-6 promoter methylation had more aggressive clinical courses than those without methylation, which was accompanied with an increasing methylation as the disease progressed. Thus, BMP-6 promoter methylation might be a potential new biomarker of risk prediction for progression to acute stages in chronic ATL patients. Larger prospective studies are desired to confirm our findings, and we plan to collect sequential samples during the clinical courses of ATL patients for the prospective study.
Although TGF- is proposed to act as a potent endogenous negative regulator of hematopoiesis, 46 its role of leukemogenesis remains largely unknown. Wolfraim et al. 47 reported that Smad3 was an important tumor suppressor in T-cell ALL. Using a Smad3 deficient mouse model, they further demonstrated that the loss of Smad3 alone was insufficient to induce leukemia. 47 However, when coupled with loss of the cyclin kinase inhibitor KIP1 expression, T-cell leukemogenesis was prompted in Smad3-deficient mice. 47 These results highlight the importance of TGF- signaling in T-cell leukemogenesis, although it is not likely that disruption of TGF- signaling alone is sufficient for the development of leukemia. 47, 48 Thus, multistep process with accumulation of oncogenic events may be necessary for the development of leukemia, as proposed in ATL leukemogenesis. 4 Their findings are interesting in respect of ATL leukemogenesis because the KIP1 gene is also mutated in acute type ATL, due to homozygous deletion and germline mutation. 12 Moreover, studies showed that impairment of TGF- signaling in ATL can be caused by suppression of Smad-dependent transcription responses by the HTLV-I-encoded Tax protein. [49] [50] [51] Thus, perturbation of TGF- signaling appears to be associated with the development and progression of ATL. Although at present we do not know how the BMP-6 promoter methylation and the resultant loss of gene expression contribute to the leukemogenesis of ATL, some speculations can be raised. Since BMP signaling is thought to be similar to the paradigm established by TGF- signaling, it is logical to assume that impairment of genes involved in the BMP pathway may predispose to development of T-cell types of leukemias.
Indeed, our results showed that promoter methylation of BMP-6 gene was observed predominantly in ATL and also in T-cell ALL although the number of T-cell ALL patients studied was relatively small. Having evidence that TGF- exerts autocrine effects on tumor cells themselves, 17, 52 it is tempting to speculate that suppressive production of endogenous 
